An observational study in Hypertension, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 21 Years to 94 Years. Per ClinicalTrials.gov, last updated 2014-09-17.
Sponsored by Boehringer Ingelheim · Observational
Primary objective: to characterize hypertensive patients treated for at least 1 month with Telmisartan (alone or in combination with other drugs) in order to define the beneficiary population (those actually receiving the treatment).
Secondary objectives:
6,834 studies on the registry are indexed under Hypertension; 971 are open to participants now.
This study's enrollment of 5,018 is above the median of 210 across 1,392 observational studies indexed under Hypertension.
Browse Hypertension studies →Boehringer Ingelheim is the lead sponsor of 2,297 studies on the registry; 56 are open to participants now.
Of its 166 completed or terminated interventional studies of FDA-regulated products, 121 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Hypertensive patients treated with Telmisartan for at least one month recruited by ceneral practitioners and cardiologists
Exclusion Criteria:
Drug: Telmisartan
Characteristics of hypertensive patients
Questionnaire to determine the beneficiary population
Time frame: Baseline, after 1 month of treatment
Changes in blood pressure
Self-monitored by patient
Time frame: Up to 1 month
Evaluation of patients satisfaction with treatment
Based on a patient 6-point self-questionnaire
Time frame: Up to 1 month
No study locations are listed for this record.
The record gives a start of Sep 2004 and a primary completion of May 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.